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Abstract
Introduction: The purpose of this study was to investigate the gene expression of interferon-gamma (IFN-g),
tumor necrosis factor-alpha (TNF-a) and interleukin-10 (IL-10) in circulating mononuclear cells harvested from septic
shock patients on drotrecogin-a activated (DAA) in order to determine whether this treatment has any effect on
the inflammation phase.
Methods: We conducted a prospective cohort study in two intensive care departments. Blood samples were
collected at inclusion (T1) and 36 hours later (T2) to measure plasma cytokines and the changes in intracellular
TNF-a, IL-10 and IFN-g mRNA expressions using the real-time quantitative polymerase chain reaction (RT-qPCR).
Thirty-two septic shock patients were included: 16 with DAA at 24 μg/kg/h for 96 hours (DAA+) and 16 control
(DAA-) eligible but contraindicated for DAA because of low platelet count.
Results: The basal characteristics were similar in both groups: mortality (50%), plasma cytokine concentrations, and
baseline IFN-g, TNF-a and IL-10 mRNA expressions (DAA+ vs. DAA-). At T2, there was a significant IFN-g gene
down-regulation in DAA+ but not in DAA- patients (-0.34 (-0.62; +1.54) vs. +1.41 (+0.35; +5.87), P = 0.008). In
survivors, DAA administration was associated with a down-expression of both IFN-g (-0.65 (-0.93; 0.48) vs. +0.7
(-0.04; +1.26), P = 0.01) and IL-10 (-0.78 (-0.92; -0.6) vs. -0.18 (-0.68; +0.46), P = 0.038). In the non-survivors, DAA
infusion was associated with IL-10 over-expression when compared with survivors (+0.54 (-0.35; +11.52) vs. -0.78
(-0.92; -0.6), P < 0.001).
Conclusions: In this study, lack of IL-10 gene down-expression despite a 36-hour infusion of DAA is an ominous
sign in septic shock patients suggesting that DAA is not able to reverse the outcome. Our results suggest that
DAA can decrease the expression of anti-inflammatory cytokines in septic shock patients. IL-10 or IFN-g gene
down-expression could represent markers of DAA response.
Introduction
To improve the outcome, continuous infusion of drotre-
cogin-a activated (DAA) is recommended for over 96 h
at a rate of 24 μg/kg/h in septic shock patients as early
as possible [1]. This dosage has raised cost/effectiveness
concerns. Yet, since DAA has been made commercially
available, in vitro studies have highlighted many more
properties for this molecule and it can no longer be
ignored [2]. A convenient biomarker of its best use
would be welcome to select patients who could truly
b e n e f i tf r o mt h i st r e a t m e n t .T h i st e s th a sn e v e rb e e n
done for several reasons: (1) single and serial measure-
ments of plasma concentrations of inflammation bio-
markers are inconsistent and do not reliably predict
outcome in septic patients [3], and (2) since the effect
of infused DAA probably changes according to the
endogenous concentration of activated protein C at any
given moment, it is currently difficult to know if
patients are responding to this drug and whether DAA
dosage should be adapted when treatment is started
without monitoring its plasma concentration over 96 h,
which is a complicated and expensive procedure.
In addition, there are methodological pitfalls in septic
shock trials relating to the diversity of sources of
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t h ei n f l a m m a t o r yr e s p o n s et r i g g e r e db yp a t h o g e n - a s s o -
ciated molecular patterns through Toll-like receptors
(TLR) activates a fast response by the nuclear factor kB
(NF-kB) pathway. Because the cellular signaling of TLRs
can be modified by polymorphism [4] and the subunits
of NF-kB expression may be affected by DAA [5], parti-
cipants in DAA clinical trials should have TLRs and
NF-kB expressions as similar as possible so that groups
can be appropriately compared. Only then will genes
targeted by the NF-kB complex be expressed on a
sound basis of comparison. Although, conclusions
would be more reliable, large clinical trials taking all
these parameters into account would be much too
expensive.
This study was conducted in real-life conditions of
septic shock management to address the following ques-
tion: does DAA have any tangible effect on the early
pro-inflammatory response to septic shock, measured as
a change in TNF-alpha (TNF-a), interferon-gamma
(INF-g), and interleukin-10 (IL-10) mRNA expressions
in circulating mononuclear cells (CMNC) harvested
from patients and true controls? If so, this would pro-
vide an early indication of improvement, and perhaps a
DAA efficiency biomarker.
Materials and methods
This study was approved by our institutional review
board for human research and informed written consent
was obtained from each participant. Patients with inher-
ited or acquired immunodeficiency were excluded.
Over one year, we included 16 consecutive patients
with septic shock [6] treated with DAA (DAA+ group)
at the standard dosage (24 μg/kg/h for 96 h), resulting
in a mean plasma DAA concentration of 45 ng/mL [2]),
and 16 patients as a control group fulfilling septic shock
criteria and eligible for DAA but contraindicated (plate-
let count < 30,000/mm
3 and/or uncontrolled bleeding).
We defined T1 as the moment within 12 h after ful-
filling septic shock criteria and before giving DAA; T2
was set 36 h later. The Simplified Acute Physiology
Score II [7], the Logistic Organ Dysfunction score [8]
and 28-day mortality were recorded.
Plasma concentrations of IL-1b,I L - 2 ,I L - 4 ,I L - 5 ,I L - 6 ,
IL-8, TNF-a,I L - 1 0 ,I F N - g and IL-12 were measured
(CBA Human inflammation kit, BD Biosciences, San
José, CA, USA) and lympho-monocytes subpopulations
determined by flow cytometry (Becton Dickinson, Run-
gis, France).
Aliquots of 20 ml of whole blood were drawn in
EDTA and, CMNC were isolated by Ficoll gradient cen-
trifugation (Eurobio, Les Ulis, France) to obtain aliquots
of 10
6 cells. RNA extraction and reverse transcription
and quantitative real-time PCR were performed with a
gene reporter (hydroxymethyl-bilane synthase, HMBS)
as reported [9]. The primers for NF-kB sub-units (p50,
p65 and IkBa) were purchased from Genome Express,
Montreuil, France. For cytokines transcriptional expres-
sion (TNF-a,I L - 1 0a n dI F N - g)Q u a n t i T e c tP r i m e r
Assays primers (Qiagen, Courtaboeuf, France) were
used. Gene expression was assessed using the 2-DDCT
method as reported [10].
The TLR-2 (G2408A) and TLR-4 (A12874G and
C13174T) polymorphisms were detected using a hybridi-
zation probe assay according to the reported method [4].
Statistical analysis
T1 and T2 gene expressions are expressed according to
previous studies [6]. Values are expressed as mean + SD
or as median and interquartile range (25 to 75). For
cytokines gene expression, results are expressed as fold
change calculated as the ratio (T2-T1)/T1. Kinetic data
were studied with analysis of variance for repeated mea-
surements (Friedman’s two-way analysis). Comparisons
of the mean were made by non-parametric tests (Mann-
Whitney U-test or Kruskal-Wallis). Association with the
genotype was sought with logistic regression. P <0 . 0 5
was considered as significant.
Results
Clinical and basic biological characteristics
Clinical characteristics of the groups are shown in Table
1. No difference between the DAA+ group and the con-
trol group was found concerning SAPS II (respectively
62.7 ± 2.8 vs 61.5 ± 3.7), LOD score (respectively 9.3 ±
0.8 vs 8.4 ± 0.8) and ICU stay (respectively 32.9 ± 8.8 vs
54.2 ± 19.3 days). The source of infection, types of germ
and number of septicaemia were statistically non-signifi-
cant between the two groups (Table 1). Mortality rate
was 50% in both groups.
TLRs polymorphisms
To assess whether TLRs polymorphism had a role in
DAA response, we searched for TLR-2 and TLR-4
polymorphisms in the DAA+ and DAA- groups.
Results are indicated in Table 1. No significant differ-
ence of distribution was found between the DAA
group and the control group regarding TLR-2 or TLR-
4 polymorphisms. Concerning TLR-4, we observed a
similar prevalence of the double mutation Asp299Gly
Thr399Ile in both DAA and control groups (Table 1)
as previously described [11].
Lymphocyte subsets
No statistical change was found between the DAA+ or
DAA- groups regarding CD4+ or CD8+ T cells subsets.
No change of T cell CD4/CD8 ratio was found over
time or between groups (data not shown).
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To establish Th1/Th2 profiles, several cytokines were
measured in serum at T1 and T2: IL-1b,I L - 2 ,I L - 4 ,
IL-5, IL-6, IL-8, TNF-a, IL-10, IFN-g and IL-12. Only
IL-1b,I L - 6 ,I L - 8 ,T N F - a,I L - 1 0a n dI F N - g showed
values above the detection threshold. No significant
change of cytokine profile was found over time between
both studied groups and regarding TLR-4 or TLR-2
polymorphisms (Table 2). We did not find any correla-
tion between intracellular mRNA expression and serum
levels of TNF-a, IL-10 and IFN-g.
Evolution of intracellular mRNA expressions
From T1 to T2, the fold changes of mRNA expressions
of p50, p65, and IkBa NF-kB subunits were not signifi-
cantly different between groups or between survivors
and non survivors (data not shown).
At T1, IFN-g,T N F - a and IL-10 mRNA expressions
were similar in both groups (DAA+ vs. DAA-). At T2,
there was a significant IFN-g gene down-regulation in
DAA+ but not in DAA- patients: -0.34(-0.62; +1.54) vs.
+1.41 (+0.35; +5.87) respectively, P = 0.008 (Figure 1).
In the survivors, DAA administration was associated
with a down-expression of both IFN-g (-0.65 (-0.93; -0.48)
vs. + 0.7 (-0.04; +1.26), P = 0.01) and IL-10 (-0.78 (-0.92;
-0.6) vs. -0.18 (-0.68; +0.46), P = 0.038) (Figure 2). In non-
survivors, there was no significant difference of expression
for the three cytokines expression with or without DAA
(Figure 3). Nevertheless, in the non-survivors, DAA infu-
sion was associated with IL-10 over-expression (+0.54
(-0.35; +11.52) vs. -0.78 (-0.92; -0.6), P = 0.038) and IFN-g
over-expression (+1.07 (+0.22; +02.79) vs. -0.65 (-0.14;
-0.78), P < 0.001) when compared with the survivors
(Figure 4).
Finally, there were no differences between the groups
for TNF-a gene expression regardless of the outcome.
Discussion
In our septic shock patients with clinical and biological
characteristics as similar as possible to real-life condi-
tions, a continuous infusion of DAA resulted in changes
in the IFN-g gene expression, suggesting that the drug
had early anti-inflammatory effects, yet IL-10 was not
significantly reduced. Moreover, when survival was con-
sidered, IL-10 dampened the pro-inflammatory reaction
of early septic shock in the survivors, whereas it failed
to do so in the non-survivors. The lack of IL-10 gene
expression decrease by CMNC is associated with an
ominous outcome even if full supportive treatment is
provided. These data suggest that: (1) DAA infusion
interferes in vivo with IFN-g and IL-10 gene expressions
through NF-kB-independent modulation, (2) continued
IL-10 and IFN-g gene expression despite a 36-h infusion
Table 1 Patient characteristics
DAA +
(n = 16)
DAA -
(n = 16)
P
Age (yr) 67.4 ｱ 4.0 67.9 ｱ 2.7 NS
SAPS II 62.7 ± 2.8 61.5 ± 3.7 NS
LOD score 9.3 ± 0.8 8.4 ± 0.8 NS
Septicaemia (n (%)) 9 (56%) 11 (69%) NS
ICU stay (days) 32.9 ± 8.8 54.2 ± 19.3 NS
Mortality at Day 28 (n (%)) 7 (43%) 8 (50%) NS
Type of bacterium : n (%)
Gram-positive 8 (50%) 6 (37%)
Gram-negative 5 (31%) 6 (37%) NS
Others (fungi) 3 (19%) 6 (37%)
Source of infection : n (%)
Pneumonia 6 (37%) 9 (56%)
Peritonitis 5 (31%) 2 (12.5%) NS
Others 5 (31%) 4 (25%)
Toll-like receptors genotyping: n
Genotype of TLR-2
(Arg753Arg/Arg753Gln/Gln753Gln)
16/0/0 16/0/0 NS
Genotype of TLR-4
(Asp299Asp/Asp299Gly/Gly299Gly)
12/4/0 15/1/0 NS
Genotype of TLR-4
(Thr399Thr/Thr399Ile/Ile399Ile)
12/4/0 15/1/0 NS
Data are means +/- SD. The respective P values result from the non-
parametric Kruskal-Wallis test, while associations with the genotype were
searched with logistic regression. SAPS II, Simplified Acute Physiology Score II
on admission; LOD score, Logistic Organ Dysfunction score; TLRs, Toll like
receptors; NS, non-significant.
Table 2 Serum cytokines level of DAA+ and control groups
DAA+
N =1 6
DAA-
N =1 6
P
T1 T2 T1 T2
TNF-alpha (pmol/mL) 15.6(13 to 22.4) 6.6(2 to 11.4) 48(29 to 66) 35(21.1 to 85) NS
IL-1 (pmol/mL) 32.1(17.1 to 54.1) 30.1(16 to 31) 39.6(20.8 to 58.3) 110.3(88.2 to 132.3) NS
IL-6 (pmol/mL) 824.5(161.5 to 507.5) 140.7(38,8 to 265) 1,885(1,102.1 to 2,500) 533.2(52 to 1,992.8) NS
IL-8 (pmol/mL) 623(102.5 to 2,348.3) 110(31.6 to 159.8) 402.3(289.1 to 754.1) 103.1(67.3 to 256.4) NS
IL-10 (pmol/mL) 47(26.2 to 54) 12.4(8.6 to 23.3) 90(44.8 to 1048.8) 26.7(8.8 to 201.1) NS
IFN-gamma (pmol/mL) 5(3 to 25) 2(2 to 3) 16(5.3 to 24) 2(2 to 3) NS
Data are expressed as median (IQR 25 to 75). DAA+, septic shock patients treated with DAA. DAA-, septic shock patients contraindicated to rhAPC treatment. T1,
time-point before DAA infusion; T2, time-point 36 h after infusion of DAA. The P-value, analysis of variance for repeated data (T1 and T2). NS, non-significant.
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fails to affect outcome.
Increased plasma concentration of cytokines such as
IFN-g, TNF-a or IL-10 is a hallmark of septic shock and
has negative consequences for recovery, although no
clinically relevant thresholds have been proposed [3,12].
However, data on plasma cytokine concentrations do
not seem to determine outcome because the exact onset
of sepsis-driven cytokines release is usually not clearly
definable in septic patients [13]. Therefore, in this study
we checked cytokine gene expression by CMNC, and
confirm that changes to them occur without conse-
quences on plasma levels in accordance with previous
studies [14]. The most significant drawbacks of this
approach are the routine availability of the RT-qPCR
technique in a hospital laboratory and the time required
to obtain the lab test result, which nevertheless takes a
few hours (less than six hours) with commercially avail-
able techniques of molecular biology.
Our data are in partial accordance with in vitro studies
that claim that DAA up-regulates IL-10 in LPS-stimulated
human monocytes [15]. Yet in vitro the DAA concentra-
tion required is significantly higher (120 ng/mL) than that
achieved in vivo with standard infusion (45 to 52 ng/mL)
[2,16]. In our setting, IL-10 gene expression was dramati-
cally increased in the non-surviving patients given DAA
suggesting either a greater IL-10 gene up-regulation by
DAA in patients with poor prognosis, or simply that DAA
has no effect on high IL-10 up-regulation by sepsis itself.
Since the baseline gene expression levels were not signifi-
cantly different between groups whatever the outcome
and treatment, we suggest that DAA has an influence that
is not necessarily powerful.
One of the limitations of our study is that it was
underpowered but our hypothesis can not be tested in a
r a n d o mf a s h i o ni nal a r g ep o p u l a t i o no fp a t i e n t ss i n c e
DAA administration can not be declined in the absence
Figure 1 Evolution of IFN-g, TNF-a and IL-10 mRNA expressions
in CMNCs from DAA + (n = 16) DAA- patients (n = 16) between
inclusion (T1) and after a 36-h DAA infusion (T2). Box and
whiskers plots show median and interquartile range (25 to 75). Fold
change is calculated as the ratio (T2-T1)/T1. DAA: drotrecogin alpha
activated. IFN-g expression is significantly reduced in the DAA+
group (*: P = 0.008, Mann-Whitney test) than in the control group.
Figure 2 Evolution of IFN-g, TNF-a and IL-10 mRNA expressions
in CMNCs from DAA + (n = 16) and DAA- patients (n = 16)
between inclusion (T1) and after a 36 h DAA infusion (T2).I n
survivors (n = 8) there is a significant lower expression of IFN-g in
the DAA+ group (*: P = 0.01, Mann-Whitney test) and also a
significant decrease of IL-10 expression in survivors (DAA+ group)
than in survivors of controls DAA- (**: P = 0.038, Mann-Whitney
test). Box and whiskers plots show median and inter quartile range
(25 to 75). Fold change is calculated as the ratio (T2-T1)/T1. DAA:
drotrecogin-a activated.
Figure 3 Evolution of IFN-g, TNF-a and IL-10 mRNA expressions
in CMNCs from DAA + (n = 16) and DAA- patients (n = 16)
between inclusion (T1) and after a 36-h DAA infusion (T2).I n
non-survivor groups (n = 8) there is no significant difference of
cytokines expression between DAA+ and control groups. Box and
whiskers plots show median and inter quartile range (25 to 75). Fold
change is calculated as the ratio (T2-T1)/T1. DAA: drotrecogin-a
activated.
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septic shock DAA may actually require a higher infusion
rate than the standard one to reach cellular efficiency
(that is, dampening IL-10 gene expression). Conversely,
DAA may have no effect on patients with continuous
IL-10 expression. Hence, maintaining DAA for 96 h as
recommended would be questionable. In both situations,
the level of IL-10 up regulation in CMNC after 36 h
DAA infusion may become a biomarker of efficiency.
T h et i m er e q u i r e dt oo b t a i nt he IL-10 gene expression
ratio is technically feasible during the working hours of
the laboratory: consequently, in a patient infused for 36
hw i t haT 2t e s ti n d i c a t i n gal a c ko fI L - 1 0a n dI F N - g
gene down-regulation, the standard DAA dosage could
be reduced after approximately half the scheduled
dosage has been infused (which would result in a 50%
saving of the drug). This warrants confirmation by a
prospective randomized placebo study including only
patients with IL-10 over expression.
Conclusions
If IL-10 and/or IFN-g gene down-expression fail to
occur despite 36 h of DAA infusion in septic shock
patients, maintaining treatment for 96 h as recom-
mended becomes questionable. IL-10 and IFN-g gene
e x p r e s s i o n sb yC M N Cc o u l db e c o m eab i o m a r k e ro f
DAA efficiency in this setting.
Key messages
￿ Drotrecogin-a (activated) has early anti-inflamma-
tory effects at the transcriptional level on circulating
mononuclear cells.
￿ Checking the transcriptome of cytokines/chemo-
kines in immune cells could be a new approach for
monitoring the effect of drotrecogin-a (activated) in
sepsis.
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